Details

Autor(en) / Beteiligte

• Harris, Isaac S.
• Treloar, Aislinn E.
• Inoue, Satoshi
• Sasaki, Masato
• Gorrini, Chiara
• Lee, Kim Chung
• Yung, Ka Yi
• Brenner, Dirk
• Knobbe-Thomsen, Christiane B.
• Cox, Maureen A.
• Elia, Andrew
• Berger, Thorsten
• Cescon, David W.
• Adeoye, Adewunmi
• Brüstle, Anne
• Molyneux, Sam D.
• Mason, Jacqueline M.
• Li, Wanda Y.
• Yamamoto, Kazuo
• Wakeham, Andrew
• Berman, Hal K.
• Khokha, Rama
• Done, Susan J.
• Kavanagh, Terrance J.
• Lam, Ching-Wan
• Mak, Tak W.

Titel

Glutathione and Thioredoxin Antioxidant Pathways Synergize to Drive Cancer Initiation and Progression

Ist Teil von

• Cancer cell, 2015-02, Vol.27 (2), p.211-222

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2015

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Controversy over the role of antioxidants in cancer has persisted for decades. Here, we demonstrate that synthesis of the antioxidant glutathione (GSH), driven by GCLM, is required for cancer initiation. Genetic loss of Gclm prevents a tumor’s ability to drive malignant transformation. Intriguingly, these findings can be replicated using an inhibitor of GSH synthesis, but only if delivered prior to cancer onset, suggesting that at later stages of tumor progression GSH becomes dispensable potentially due to compensation from alternative antioxidant pathways. Remarkably, combined inhibition of GSH and thioredoxin antioxidant pathways leads to a synergistic cancer cell death in vitro and in vivo, demonstrating the importance of these two antioxidants to tumor progression and as potential targets for therapeutic intervention. [Display omitted] •The GSH antioxidant pathway is required for cancer initiation•After cancer initiation, GSH is dispensable due to alternative antioxidant pathways•The TXN antioxidant pathway is upregulated in tumors•Inhibition of both GSH and TXN pathways causes synergistic cancer cell death Harris et al. show that the antioxidant glutathione (GSH) is required for cancer initiation but not for established tumors partly due to upregulation of the thioredoxin (TXN) antioxidant pathway in the latter. Consequently, blocking both GSH and TXN pathways synergistically inhibits tumor growth.